Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: Modeling T cell immunotherapy in vivo

Journal of Medical Virology

Volumn 83, Issue 9, 2011, Pages 1585-1596

  Johannessen, I ^a,b   Bieleski, L ^a   Urquhart, G ^a   Watson, S L ^a   Wingate, P ^a   Haque, T ^a   Crawford, D H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

B cell lymphoma; Epstein Barr virus; Immunotherapy; SCID mouse

Indexed keywords

CD20 ANTIGEN; CD45 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOPROLIFERATIVE DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; NORMAL HUMAN; POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE; SCID MOUSE;

ANIMALS; B-LYMPHOCYTES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; IMMUNOTHERAPY; IN SITU HYBRIDIZATION; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-7; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, SCID; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; HUMAN HERPESVIRUS 4; MUS;

EID: 79960138185     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22164     Document Type: Article

References (41)

1. Appay V. 2004. The physiological role of cytotoxic CD4+ T-cells: The holy grail? Clin Exp Immunol 138: 10-13.
2. Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, Romero P, Cerottini JC, Rammensee HG, Pfreundschuh M, Speiser D, Levy F. 2002. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol 168: 1717-1722.
3. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. 1998. EBV persistence in memory B cells in vivo. Immunity 9: 395-404.
4. Baiocchi RA, Caligiuri MA. 1994. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci USA 91: 5577-5581.
5. Baiocchi RA, Ward JS, Carrodeguas L, Eisenbeis CF, Peng R, Roychowdhury S, Vourganti S, Sekula T, O'Brien M, Moeschberger M, Caligiuri MA. 2001. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. J Clin Invest 108: 887-894.
6. Bickham K, Munz C, Tsang ML, Larsson M, Fonteneau J-F, Bhardwaj N, Steinman R. 2001. EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin Invest 107: 121-130.
7. Bogedain C, Wolf H, Modrow S, Stuber G, Jilg W. 1995. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol 69: 4872-4879.
8. Bosma GC, Custer RP, Bosma MJ. 1983. A severe combined immunodeficiency mutation in the mouse. Nature 301: 527-530.
9. Boyle TJ, Berend KR, DiMaio M, Coles RE, Via DF, Lyerly HK. 1993. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery 114: 218-226.
10. Buchsbaum RJ, Fabry JA, Lieberman J. 1996. EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice. Immunol Lett 52: 145-152.
11. Cannon MJ, Pisa P, Fox RI, Cooper NR. 1990. Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in scid/hu chimeric mice. J Clin Invest 85: 1333-1337.
12. Crawford DH, Macsween KF, Higgins CD, Thomas R, McAulay K, Williams H, Harrison N, Reid S, Conacher M, Douglas J, Swerdlow AJ. 2006. A cohort study among university students: Identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 43: 276-282.
13. DiMaio JM, Trigt PV, Gaynor JW, Davis RD, Coveney E, Clary BM, Lyerly HK. 1995. Generation of tumour-specific T lymphocytes for the treatment of posttransplant lymphoma. Circulation 92: II202-II205.
14. Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A, Dombagoda D, Britton KM, Swerdlow AJ, Crawford DH. 2002. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly MHC-matched allogeneic cytotoxic T cells. Lancet 360: 436-442.
15. Haque T, Wilkie GM, Morton-Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, Macgilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH. 2007. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131.
16. Henle G, Henle W. 1966. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 91: 1248-1256.
17. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. 2002. Epitope-specific evolution of human CD8+ T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 195: 893-905.
18. Johannessen I, Asghar M, Crawford DH. 2000. Essential role for T cells in human B cell lymphoproliferative disease development in SCID mice. Br J Haematol 109: 600-610.
19. Johannessen I, Perera SM, Gallagher A, Hopwood PA, Thomas JA, Crawford DH. 2002. Expansion in SCID mice of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease biopsy material. J Gen Virol 83: 173-178.
20. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagay Y, Rosenberg SA, Waldmann TA, Restifo NP. 2004. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 101: 1969-1974.
21. Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A, Balatoni J, Teruya-Feldstein J, Heller G, May C, Ponomarev V, Ruan S, Finn R, Blasberg RG, Bornmann W, Riviere I, Sadelain M, O'Reilly RJ, Larson SM, Gelovani Tjuvajev JG. 2003. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol 21: 405-413.
22. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P. 2000. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 288: 675-678.
23. Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, ÓReilly RJ. 1996. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C. B-17 SCID/SCID mice. J Exp Med 183: 1215-1228.
24. Mansoor W, Gilham DE, Thistlethwaite FC, Hawkins RE. 2005. Engineering T cells for cancer therapy. Br J Cancer 93: 1085-1091.
25. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. 1988. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335: 256-259.
26. Moss DJ, Burrows SR, Silins SL, Misko I, Khanna R. 2001. The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond B Biol Sci 356: 475-488.
27. Murray RJ, Kurilla MG, Griffin HM, Brooks JM, Mackett M, Arrand JR, Rowe M, Burrows SR, Moss DJ, Kieff E, Rickinson AB. 1990. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc Natl Acad Sci USA 87: 2906-2910.
28. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 176: 157-168.
29. Parada NA, Center DM, Kornfeld H, Rodriguez WL, Cook J, Vallen M, Cruikshank WW. 1998. Synergistic activation of CD4+ T cells by IL-16 and IL-2. J Immunol 160: 2115-2120.
30. Picchio G, Kobayashi R, Kirven M, Baird SM, Kipps TJ, Mosier DE. 1992. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in scid mice receiving human peripheral blood leukocyte grafts. Cancer Res 52: 2468-2477.
31. Rencher SD, Slobod KS, Smith FS, Hurwitz JL. 1994. Activity of transplanted CD8+ versus CD4+ cytotoxic T cells against Epstein-Barr virus-immortalized B cell tumors in SCID mice. Transplantation 58: 629-633.
32. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE. 1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555.
33. Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson AB. 1991. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the scid mouse model: Implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 173: 147-158.
34. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. 2000. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 1: 426-432.
35. Schumacher TNM. 2002. T-cell-receptor gene therapy. Nat Rev Immunol 2: 512-519.
36. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. 1997. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 185: 1605-1617.
37. Thomas JA, Hotchin NA, Allday MJ, Amlot P, Rose M, Yacoub M, Crawford DH. 1990. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 49: 944-953.
38. Thomas JA, Crawford DH, Burke M. 1995. Clinicopathologic implications of Epstein-Barr virus related B cell lymphoma in immunocompromised patients. J Clin Pathol 48: 287-290.
39. Wagar EJ, Cromwell MA, Shultz LD, Woda BA, Sullivan JL, Hesselton RM, Greinier DL. 2000. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in hu-PBL-SCID mice. J Immunol 165: 518-527.
40. Wilkie GM, Taylor C, Jones MM, Burns DM, Turner M, Kilpatrick D, Amlot PL, Crawford DH, Haque T. 2004. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. J Immunother 27: 309-316.
41. Williams H, Crawford DH. 2006. Epstein-Barr virus: The impact of scientific advances on clinical practice. Blood 107: 862-869.